Improving Treatment Adherence in Your Patients with Schizophrenia-Reference-Cited by-同舟云学术

Improving Treatment Adherence in Your Patients with Schizophrenia

Published:2013-01-04 Issue:2 Volume:33 Page:97-107
ISSN:1173-2563
Container-title:Clinical Drug Investigation
language:en
Short-container-title:Clinical Drug Investigation

Author:

Cañas Fernando,Alptekin Koksal,Azorin Jean Michel,Dubois Vincent,Emsley Robin,García Antonio G.,Gorwood Philip,Haddad Peter M.,Naber Dieter,Olivares José M.,Papageorgiou Georgios,Roca Miquel

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s40261-012-0047-8.pdf

Reference92 articles.

1. Valenstein M, Ganoczy D, McCarthy JF, et al. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry. 2006;67(10):1542–50.

2. National Institute for Health and Clinical Excellence (NICE) 2009. Medicines Adherence Clinical Guideline CG76. Available from URL: http://www.nice.org.uk/nicemedia/live/11766/42891/42891.PDF [Accessed 2012 Nov 14].

3. Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand. 2002;106(4):286–90.

4. Weiden PJ, Zygmut A. Medication noncompliance in schizophrenia. Part I: Assessment. J Pract Psych Behav Health. 1997;3:106–10.

5. Peuskens J, Olivares JM, Pecanak J, et al. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. Curr Med Res Opin. 2010;26(3):501–9.

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment adherence rates across different psychiatric disorders and settings: findings from a large patient cohort;International Clinical Psychopharmacology;2024-05-30

2. Schizophrenia and medication adherence: Associated factors;Archives of Psychiatric Nursing;2024-04

3. The effects of the COVID-19 pandemic on hallucinations and delusions in youth at clinical high-risk for psychosis and outpatients with schizophrenia;European Archives of Psychiatry and Clinical Neuroscience;2023-01-21

4. New approaches to antipsychotic medication adherence – safety, tolerability and acceptability;Expert Opinion on Drug Safety;2021-09-29

5. Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia;CNS Drugs;2021-09-21